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ABSTRAK 
 
 D6 dan DARC telah dilaporkan sebagai penarik reseptor kemokina dalam 
kajian kanser. Penglibatan D6 dan DARC dalam kanser payudara telah dikaji dan 
dilaporkan berkorelasi negatif dengan perkembangan dan metastasis sel kanser payudara. 
Kajian ini bertujuan membina klon rekombinan D6 dan DARC, mengekspres, 
menganalisis dan menulenkan protein rekombinan dan kemudian menentukan kesan 
protein rekombinan ke atas migrasi dan invasi sel kanser payudara. Gen D6 dan DARC 
dalam sel MDA-MB-231 diamplifikasikan oleh RT-PCR satu-langkah dengan primer 
gen spesifik dan polimerase Pfu DNA pada mulanya. Selain itu, DARC juga 
diamplifikasikan dengan PCR menggunakan polimerase DNA Phusion. Bagi setiap klon, 
dua pasang primer spesifik digunakan untuk menghasilkan jujukan nukleotida penuh 
yang kemudian diklonkan ke dalam vektor ekspresi pPICZ dan pPICZα. Pembinaan klon 
TA dan analisis penjujukan DNA menunjukkan pemadanan sempurna antara TA-D6 dan 
TA-D6α dengan jujukan DNA rujukan. Walau bagaimanapun, penggantian bes 
diperhatikan pada lokasi 131 bp TA-DARC dan TA-DARCα. Mutagenesis tapak terarah 
telah dijalankan untuk membetulkan  ketidakpadanan itu. Penjanaan vektor ekspresi yis 
rekombinan dilakukan dan penjujukan DNA dijalankan semula untuk mengesahkan 
ligasi sebingkai gen yang diingini dengan jujukan hujung N dan C vektor-vektor 
xxiii 
ekspresi. Analisis ClustalW sekali lagi menunjukkan ketidakpadanan pada 131 bp 
pPICZ-DARC dan pPICZ-DARCα, selaras dengan penemuan TA-DARC dan TA-
DARCα. Ini mencadangkan bahawa penggantian bes yang ditemui bukan satu 
ketidakpadanan tetapi mungkin merupakan polimorfisme di mana jujukan nukleotida 
DARC daripada sel MDA-MB-231 mempunyai satu nukleotida yang berlainan pada 131 
bp dan jujukan gen tersebut telah disimpan dalam GeneBank (ID: JX081310). Selepas 
itu, elektrotransformasi Pichia GS115 telah dijalankan untuk membolehkan integrasi 
vektor ekspresi yis rekombinan linear ke dalam genom yis. Selepas penyaringan 
antibiotik dan analisis PCR untuk mengesahkan integrasi gen yang diingini dalam 
genom yis, klon-klon positif dikulturkan atas medium dengan peningkatan kepekatan 
Zeocin
TM
. Klon-klon yang dapat merintang kepekatan Zeocin
TM
 sehingga 2 mg/ml 
dipilih untuk ekspresi protein rekombinasi. Profil awal ekspresi protein rekombinan 
menunjukkan penghasilan protein heterologus yang rendah oleh klon pPICZα. Oleh itu, 
hanya klon pPICZ yang menghasilkan protein rekombinan intraselular dipilih untuk 
kajian ekspresi selanjutnya. Pengoptimuman parameter fizikal dan kimia terpilih telah 
dilakukan dan ekspresi protein rekombinan intraselular terlarut didapati meningkat 
secara mendadak dengan peningkatan sebanyak 1011.97% untuk klon rekombinan D6, 
451.75% untuk klon rekombinan DARC dan 394.72% untuk klon rekombinan DARC 
bermutasi. Parameter yang dioptimumkan ialah: BMMY pada pH 6.0, saiz inokulum 
pada OD600 2.5 (untuk D6) dan 1.0 (untuk DARC dan DARC bermutasi), induksi dengan 
1.0% (v/v) metanol sekali setiap 24 jam dan inkubasi pada 16°C selama 48 jam. Protein 
rekombinan kemudian ditulenkan dengan menggunakan kromatografi afiniti dengan 
resin Cobalt. Analisis SDS PAGE dan Western Blot yang telah dioptimumkan 
menunjukkan bahawa rekombinan D6, DARC dan DARC bermutasi hasilan yis yang 
xxiv 
telah ditulenkan mempunyai berat molekul yang lebih tinggi berbanding dengan berat 
molekul  kiraan teori. Selepas itu, protein rekombinan yang telah ditulenkan digunakan 
dalam kajian berasaskan sel untuk menguji aktiviti biologinya. Ujian viabiliti sel 
menunjukkan bahawa rekombinan D6, DARC dan DARC bermutasi tidak 
mempengaruhi viabiliti sel dengan ketara dan dengan itu mencadangkan bahawa mereka 
tidak terlibat dalam kematian sel kanser payudara. Ujian penyembuhan luka 
menunjukkan bahawa kehadiran rekombinan D6, DARC atau DARC bermutasi pada 10 
μg/ml menghalang migrasi sel kanser payudara dengan optimumnya. Kajian ELISA 
menunjukkan hubungan songsang antara protein-protein rekombinan dengan tahap 
CCL2 dalam sel yang dirawat. Ujian migrasi menggunakan “Boyden chamber” 
memaparkan fungsi protein rekombinan dalam merencat aktiviti kemotaksis sel-sel yang 
dirawat. Ujian invasi menggunakan “Boyden chamber” yang dilapisi matrigel 
menunjukkan keupayaan protein rekombinan dalam  menyekat  invasi sel yang dirawat. 
Dalam perbandingan kesan tunggal dan kesan kombinasi protein rekombinan, gabungan 
D6 dan DARC pada nisbah 1:1 (10 μg/ml) didapati paling baik dalam mengurangkan 
tahap CCL2 dalam sel-sel yang dirawat dan seterusnya menghalang migrasi dan invasi 
sel-sel yang dirawat. Ini telah menunjukkan bahawa rekombinan D6, DARC dan DARC 
bermutasi hasilan yis yang ditulenkan bukan sahaja bertindak sebagai pengawal selia 
negatif bagi migrasi dan invasi sel kanser payudara malah kesan perencatannya adalah 
lebih tinggi apabila digunakan bersama. 
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ABSTRACT 
 
D6 and DARC had been reported as a decoy chemokine receptor in cancer study. 
The involvement of D6 and DARC in breast cancer had been investigated and it was 
reported to negatively correlate with the progression and metastasis of breast cancer 
cells. This study aimed to construct recombinant clones of D6 and DARC, express, 
analyze and purify the proteins and then determine the effects of the recombinant 
proteins on breast cancer cell migration and invasion. D6 and DARC genes in MDA-
MB-231 cell line were first amplified by one-step RT-PCR with gene specific primers 
and Pfu DNA polymerase. Besides, DARC was also amplified by PCR using Phusion 
DNA polymerase. For each of the clones, two pairs of specific primers were used to 
generate full length nucleotide sequences which were cloned into pPICZ and pPICZα 
expression vectors. The construction of TA clones and DNA sequencing analysis 
showed perfect match of TA-D6 and TA-D6α to reference sequence. However a base 
substitution was observed at 131 bp of TA-DARC and TA-DARCα. Site-directed 
mutagenesis was carried out to correct the mismatch. Generation of recombinant yeast 
expression vector was performed and DNA sequencing was carried out again to confirm 
in frame ligation of gene of interest to the N and C-terminal sequences of expression 
vectors. ClustalW analysis again showed a mismatch at 131 bp of pPICZ-DARC and 
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pPICZ-DARCα, which was identical to the findings of TA-DARC and TA-DARCα. 
This suggested that the base substitution found was not a mismatch but might be a 
polymorphism where the nucleotide sequence of DARC from MDA-MB-231 cells 
posses a different nucleotide at 131 bp and the gene sequence had been deposited to 
GeneBank (ID: JX081310). After that, electrotransformation of Pichia GS115 was 
carried out to allow integration of linearized recombinant yeast expression vectors into 
yeast genome. Upon antibiotic screening and PCR analysis to confirm the integration of 
gene of interest in the yeast genome, the positive clones were plated at increasing 
Zeocin
TM
 concentrations. Clones which were able to confer resistance to Zeocin
TM
 
concentration of up to 2 mg/ml were selected for recombinant protein expression. Initial 
profile of recombinant protein expression showed low yields of heterologous proteins 
from pPICZα clones. Hence, only pPICZ clones, which expressed recombinant protein 
intracellularly were selected for further expression studies. Optimizations of selected 
physical and chemical parameters were performed and the intracellular expression of 
soluble recombinant proteins were found to increase dramatically with an increase of 
1011.97% for recombinant D6, 451.75% for recombinant DARC and 394.72% for 
recombinant mutated DARC. The optimized parameters are: BMMY at pH 6.0, 
inoculum size at OD600 of 2.5 (for D6) and 1.0 (for DARC and mutated DARC), 
induction with 1.0% (v/v) of methanol once every 24 hours and incubated at 16°C for 48 
hours. The recombinant proteins were then purified by using affinity chromatography 
with Cobalt resins. SDS PAGE analysis and optimized Western Blot showed that the 
purified yeast expressed recombinant D6, DARC and mutated DARC were higher in 
apparent molecular weight compared to the theoretical calculated molecular weight. The 
purified recombinant proteins were then used in cell based studies to test on its 
xxvii 
biological activity. Cell viability tests showed that recombinant D6, DARC and mutated 
DARC did not affect the viability of cells significantly and thus suggested that they were 
not involved in breast cancer cell death. Wound healing assays showed that the presence 
of recombinant D6, DARC or mutated DARC at 10 µg/ml inhibited the migration of 
breast cancer cells optimally. ELISA showed the inverse relationship between the 
recombinant proteins and CCL2 level in treated cells. Migration assay using Boyden 
chamber demonstrated the function of the recombinant proteins in inhibiting chemotaxis 
activity of treated cells. Invasion assay using matrigel coated Boyden chamber further 
showed the ability of the recombinant proteins in inhibiting the invasion property of 
treated cells. Comparing single and combinatorial effects of the recombinant proteins, 
the combination of D6 and DARC at ratio 1:1 (10 µg/ml) was found to be the best in 
reducing CCL2 level in treated cells and subsequently inhibit the migration and invasion 
of treated cells. It was shown that the purified yeast expressed recombinant D6, DARC 
and mutated DARC are not only negative regulators of breast cancer cell migration and 
invasion but the inhibition effects were greater when they were used in combination. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Breast cancer 
Breast cancer is the most common cancer in women in most parts of the world. 
Majority of the breast cancer patients were found to surrender to this disease due to 
cancer invasion and metastasis (Chew et al., 2013). In oncology study, breast cancer 
research had become one of the most evolving fields (Vora et al., 2009). To date, with 
the advanced understanding of key molecular features, breast cancer is no longer 
considered a single disease but a combination of different subtypes with different 
biological behaviours and clinical outcomes (Sandhu et al., 2010). Novel molecules and 
new diagnostic methods are being discovered and developed constantly, globally. 
Recently, the identification of various signaling pathways implicated in the cellular 
processes of breast cancer cells has drawn the attention of researchers worldwide. The 
involvement of growth factors or signaling molecules in breast cancer cell proliferation 
and invasion were reported worldwide (Adams et al., 1991; Adnane et al., 1991; 
Cabioglu et al., 2009; Ahmad et al., 2011). For examples, chemokines and chemokine 
receptors were reported to be involved in cancer growth and metastasis (Addison et al., 
2004; Balkwill, 2004; Ali and Lazennec, 2007; Allavena et al., 2011; Tang et al., 2011; 
Zeng et al., 2011). Noteworthy attention had been placed on mediators which are known 
to be inflammatory, such as cytokines and chemokines (Balkwill and Mantovani, 2001; 
Coussens and Werb, 2002; Allavena et al., 2008). 
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 1.1.1 Breast cancer in Malaysia 
Ho et al. (2017) reported that breast cancer is the fourth leading cause of death in 
Malaysia. According to the Malaysia Breast Health Information Centre, there is a 
marked geographical variation in the breast cancer incidence rate where the statistics are 
more frightening in Western countries, such as the U.S., than in developing countries. In 
the U.S., approximately 184,000 new breast cancer cases are detected annually. The 
breast cancer incidence is also rising in Malaysia. Malaysian National Cancer Registry 
Report 2007-2011 (Azizah et al., 2016) showed that breast cancer is the most common 
cancer among females in Malaysia during the period of 2007-2011. Colorectal, cervix 
uteri, ovary and lung cancer are the other 4 common cancers after breast cancer. 
According to the report, breast cancer constituted 32.1% of all the cancers in Malaysian 
females. 56.9% of the breast cancer cases were detected at stage I and stage II. Breast 
cancer incidence was found to be the highest in Chinese females followed by Indian and 
Malay. Moreover, the report also showed that the highest cumulative risk was observed 
in Chinese females and the lowest in Malay females. Furthermore, lifetime risk was 
found to be 1 in 30 as a big total. Lifetime risk in Chinese was 1 in 22, 1 in 24 for Indian 
and Malay was observed to be 1 in 35. The age-standardization rate (ASR) distribution 
according to state among female breast cancers in Malaysia from year 2007-2011 is 
presented in Figure 1.1. 
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Adopted from Azizah et al. (2016) 
 
Figure 1.1 The age-standardization rate (ASR) distribution according to state in 
Malaysia, 2007-2011 
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1.1.2 Breast cancer studies in Malaysia 
According to the Cancer Research Initiatives Foundation (CARIF), current breast 
cancer research in Malaysia includes: 
• Determination of genes that cause breast cancer and contribute to an increased 
risk of breast cancer. 
• Identification of biomarkers that may be used in identification and early 
detection of breast cancer and development of these biomarkers into clinically 
useful tools. 
• Identification and development of methods for the rapid and robust identification 
of individuals who are at risk of breast cancer. 
• Development of appropriate screening, preventive and therapeutic strategies for 
individuals who are at high risk for breast cancer. 
• Discovering ways to prevent and treat breast cancer such as using drugs, plant 
extracts, herbal tualang honey and other traditional medicines. 
 
However, investigation of the invasiveness of breast cancer cells by targeting the 
invasion-associated molecules, such as CCL2 remains rare. 
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1.2 Chemokines and chemokine receptors in cancer  
Chemokines are small proteins range from approximately 8 to 17 kDa and 
belong to a family of chemoattractant cytokines, which can be induced by cytokines, 
growth factors and pathogenic stimuli. Chemokines mostly involved in chemoattraction 
to regulate the migration of cells, particularly leukocyte, to inflammation sites (Luster, 
1998). Charo and Ransohoff (2006) reported that chemokines were also involved in 
other cytokine-like activitives, such as proliferation, apoptosis susceptibility, 
angiogenesis and fibrosis. Chemokine structure comprises an N‑terminal loop region, 
three-strand antiparallel β-sheets forming the typical core fold of the chemokines and a 
C‑terminal α helix which overlays the β-sheet. The production of chemokines can be 
either constitutive or induced by environmental stimuli. Thus, chemokines can be 
subdivided into two major categories, namely homeostatic and inflammatory 
chemokines. Constitutive chemokines always regulate homeostatic trafficking of 
leukocytes and lymphocyte recirculation under normal or steady state condition; 
whereas inflammatory chemokines are generated in response to inflammatory and 
immune stimuli which subsequently direct leukocytes to inflammed peripheral tissues 
(Chew et al., 2013). Chemokines are classified into four subfamilies, C, CC, CXC and 
CX3C (where X is any amino acid), based on the number and spacing of the first two 
cysteines in the amino terminus (Slettenaar and Wilson, 2006). The schematic 
representation of these four different groups of chemokines is shown in Figure 1.2.  
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Adopted from Ali and Lazennec (2007) 
 
Figure 1.2 Chemokines are classified into four major groups, namely CXC, CC, 
CX3C and XC (where X is any amino acid) 
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Besides leukocyte chemoattraction, Ali and Lazennec (2007) reviewed that 
chemokines were the first members of the cytokine family to show interaction with G-
protein-coupled receptors (GPRC). These chemokine receptors are known to be 
embedded in the lipid bilayer of the cell surface and also to possess seven 
transmembrane domains. These members of G-protein-coupled receptor (GPCR) 
superfamily have single polypeptide chains that consist of three extracellular loops and 
also three intracellular loops. There is also a serine/threonine-rich intracellular carboxyl-
terminal domain and an acidic amino-terminal extracellular domain which is involved in 
the binding of ligand. Besides, there are important conserved motifs in chemokine 
receptors, such as Thr-X-Pro; where X refers to any amino acid, Asp-Arg-Tyr (DRY) 
and Glu-Leu-Arg (ELR) (Figure 1.3). These conserved motifs play a role in signaling. 
 
Figure 1.3 depicted the interaction of chemokine receptors with endothelial cells. 
Chemokines interact with endothelial cells via glycosaminoglycans (GAGs). Some 
chemokines bind GAGs through C-terminal α-helix amino acids, whereas other 
chemokines bind GAGs via residues in the loop that links N terminus with the first β-
strand and residues in the loop which links to second and third β-strands (Mantovani et 
al., 2006). 
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Adopted from Mantovani et al. (2006) 
 
Figure 1.3 The interaction of chemokine receptors with endothelial cells 
(a) Some chemokines bind GAGs through C-terminal α-helix 
amino acids 
(b) Some chemokines bind GAGs via residues in the loop that 
links N terminus with the first β-strand and residues in the 
loop which links to second and third β-strands. 
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Chemokines bind to the seven transmembrane spanning G-protein-coupled receptors 
(GPCRs) to exert their actions. Typical receptor then specifically binds to its ligand 
leading to typical signaling pathways. Upon binding of chemokine receptor to its ligand, 
the βγ subunits of heterotrimeric G-protein were released. The detached βγ subunits 
activate phosphoinositide-specific phospholipase C (PLC) isoenzymes directly. This 
leads to the formation of inositol-1, 4, 5-triphosphate. The rise of intracellular calcium 
concentration subsequently leads to chemotaxis (Ali and Lazennec, 2007; Yadav et al., 
2010). However, PI3K pathway is another alternative. Activation of MAP Kinase 
pathway following PI3K will ultimately leads to chemotaxis too (Roussos et al., 2011) 
(Figure 1.4).  The short and transient signals mediated by the chemokine receptor to 
induce chemotaxis can be terminated rapidly by phosphorylation at multiple sites of the 
cytoplasmic C-terminus, homologous and heterologous desensitization and 
internalization eventually (Yadav et al., 2010). 
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Adopted from Ali and Lazennec (2007) 
Figure 1.4 The binding of chemokine receptor to respective ligand elicits a cascade 
of signaling pathways 
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Allavena et al. (2011) reported that serving as key-player in cancer-related 
inflammations, chemokines was found affecting a variety of tumor progression pathways. 
Those pathways include cancer cell survival and proliferation, cell migration and cell 
invasion. Chemokine ligands and its receptors are plentifully expressed in cancer cells of 
chronic inflammatory conditions. 
 
In the recent years, chemokines and chemokine receptors have been widely 
reported on their roles in the process of malignant progression (Muller et al., 2001; Ben-
Baruch, 2006; Rollins, 2006; Ali and Lazennec, 2007; Ben-Baruch, 2008). Cancer cells 
were observed to produce chemokines and chemokine receptors which were able to 
response specifically to these chemokines, thus forming a complex chemokine network 
which is involved in influencing tumuor cell survival, spreading and growth (Balkwill, 
2004). Typical receptor binds specifically to its ligand and leading to typical signaling 
pathway.  However, a few “silent” receptors are included in chemokine system as they 
bind to respective ligands with high affinity but do not bring out signal transduction. The 
details on these silent receptors are discussed in Section 1.4. 
 
 Raman et al. (2011) stated that chemokines play a vital role in physiology, 
homeostasis and also pathogenesis of tumors and their metastasis. The applications of 
chemokines and chemokine receptors in pre-clinical and clinical settings suggested 
chemokine system as an important target for the improvement of current therapeutic 
strategies (Allavena, 2011).  
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 1.2.1 CCL2 and breast cancer 
Chemokine (C-C motif) ligand 2 (CCL2), also referred to as monocyte 
chemotactic protein-1 (MCP-1), is a member of the C-C chemokine family and is 
primarily secreted by monocytes, macrophages and dendritic cells (Conti and Rollins, 
2004). It is known as a potent chemoattractant for monocytes, memory T-lymphocytes 
and also natural killer cells (NK cells). It is one of the soluble growth factors, detected in 
high level in serum and not presented on cell surface (Jiang et al., 1990; Jiang et al., 
1991; Proost et al., 2006). An elevated serum level of CCL2 has been found to be 
significantly associated with breast cancer invasion and metastasis and higher 
tumorigenicity phenotype of breast cancer cells (Neumark et al., 1999; Wang et al., 
2006). CCL2 expression in breast carcinomas was reported to correlate with the lack of 
estrogen receptor (ER) and expression of progesterone receptor (Chavey et al., 2007). 
 
The tumor associated macrophages (TAM) are myeloid monocytic cells which 
are employed to the tumor cells via CCL2. TAM was correlated to invasive phenotype 
and poor diagnosis (Mantovani et al., 2006b; Sozzani et al., 2007; Lewis and Pollard, 
2006). Besides serving the role as pro-maglinancy in breast cancer, CCL2 expressed by 
TAM and/or tumor cells was observed to significantly correlate with microvessel density 
and vessel invasion of tumor cells (Saji et al., 2001; Balkwill, 2004; Wang et al., 2006; 
Wu et al., 2008; Galzi et al., 2010; Mantovani et al., 2010; Ueno et al., 2000).  TAM-
expressed CCL2 was also found to be significantly related to the expression of 
membrane type 1-matrix metalloproteinase (MT1-MMP), tumor necrosis factor α 
(TNFα), thymidine phosphorylase (TP) and other angiogenic factors.  
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Figure 1.5 showed the suggested mechanisms interceding roles of CCL2 and 
breast cancer.  Different from normal breast cells, breast cancer cells express CCL2 in 
high level. Besides, CCL2 was also released by different cells types at the tumor 
microenvironment. Figure 1.5A showed that CCL2 promotes angiogenesis and 
stimulates the tumor cells to release MMP, subsequently induces the motility of tumor 
cells. This explains the roles of CCL2 in breast cancer cell migration and invasion. 
Activities of CCL2 further aggravate the effects of TAM-derived pro-maglinancy factors 
at the tumor sites (Figure 1.5B). This lead to the growth and establishment of tumor cells 
at primary tumor sites. Tumor cell migration and dissemination also take place. 
Ultimately, the tumor-promoting activities of CCL2 lead to metastatic spread of tumor 
cells to preferred metastatic sites such as lungs, bones and liver (Figure 1.5C) 
 
In summary, CCL2 plays a causative role in the maglinancy of breast cancer 
(Soria and Ben-Baruch, 2008). Nam et al. (2006) used MDA-MB-231, the metastatic 
human breast cancer cells to study the direct effect of CCL2 in breast cancer maglinancy. 
CCL2 knocked down by shRNA in the study was observed to result in approximately 3-
fold decrease of metastatic lung nodules in mice. Salcedo et al. (2000) reported 
significant inhibition of lung metastasis and increment of mice survival rate with CCL2 
blocking by neutralizing antibodies in MDA-MB-231 cells.  
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Adopted from Soria and Ben-Baruch (2008) 
Figure 1.5 Roles of CCL2 on the maglinancy of breast cancer 
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1.3 Role of chemokines and chemokine receptors in cancer cell migration and 
invasion 
 Expression of chemokine receptors has been found to be restricted and specific 
in many cancer cells. Beside aiding in cell growth and survival, chemokine receptors 
were also found to be facilitating the characteristic patterns of metastasis (Slettenaar and 
Wilson, 2006). 
 
To date, CXCR4 is the most overexpressed and best characterized chemokine 
receptor in cancer cells that demonstrated the involvement of CXCR4 in cancer cells 
metastasis. CXCR4 was found up regulated in more than 20 different types of tumor 
histotypes (Mantovani et al., 2010). In hematopoietic stem cells, CXCR4 was used to 
reach and settle down in bone marrow niches. The expression of CXCR4 in primary 
tumor has shown positive co-relationship with the degree of lymph node metastasis, 
poor patient overall survival and also tumor grade (Ali and Lazennec, 2007). Besides, 
the expression of CXCR4 had also been linked to the metastasis ability of breast cancer 
cells to the lung (Helbig et al., 2003). 
 
Other CXC chemokine receptors had also been reported in the malignancy of 
different types of hematological neoplasia either alone or in combination. For examples, 
CXCR and CXCR2 in malignant melanoma (Varney et al., 2006), CCR5, CCR9 and 
CX3CR1 in prostate cancer (Murphy et al., 2005). Besides, CXCR3 was found to be 
associated with the development of lymph node metastasis in murine melanoma 
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(Kawada et al., 2004) and colon cancer (Kawada et al., 2007) and lung metastasis in 
murine mammary cancer models (Walser et al., 2006; Ma et al., 2009). Apart from that, 
CXCR5 had been observed to promote liver metastasis of colorectal carcinoma (Meijer 
et al., 2006) whereas CXCR6 was found to be associated with inhibition of tumor 
growth in breast and renal cancer (Meijer et al., 2008; Gutwein et al., 2009) but up 
regulated in advanced stage of prostate cancer (Darash-Yahana et al., 2009). 
 
CCR7 had been used as a potential marker in prediction of breast and colorectal 
cancer (Gunther et al., 2005). Lower survival rates were observed from patients with 
CCR7 positive carcinomas than those with CCR7 negative cancer cells. Besides, CCR7 
was also found to be associated with lymph node metastasization, lymphatic invasion 
and also stage of tumor (Takanami, 2003). Other CC chemokine receptor such as CCR6 
was observed to play significant roles in organ selective liver metastasis of colorectal 
cancer (Ghadjar et al., 2006). CCR9 was reported to be related to intestinal melanoma 
metastasis (Letsch et al., 2004) while CCR5-positive cancer cells were observed to 
enhance the growth and metastatic ability of tumor cells upon interacting with CCL5 
(Karnoub et al., 2007). Besides, the expression of CX3CR1 by prostate cancer cells was 
observed to mediate metastasis to bone (Shulby et al., 2004). It was also reported to be 
expressed by pancreatic adenocarcinoma and was implicated in perineural invasion and 
tumor recurrence (Marchesi et al., 2008). 
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1.4  Decoy chemokine receptor proteins 
Many studies have recently reported findings on the atypical action of chemokine 
receptor proteins (Figure 1.6). These receptor proteins were termed “decoy proteins” or 
“scavenger proteins” due to the fact that the binding of these proteins to the respective 
ligands does not lead to typical signaling pathway, but intercept the respective pathway 
and neutralize the action of chemokines (Wang et al., 1998; Mantovani et al., 2006; 
Wang et al., 2006; Wu et al., 2008; Galzi et al., 2010). Hence they are also well known 
to be “intercepting receptors” as the decoy chemokine receptors confiscate chemokines 
with no activation of respective signaling pathway (Galzi et al., 2010; Hansell et al., 
2006). The binding of chemokines without triggering G protein signaling pathway is a 
way of regulating chemokine activity and may function as a tumor suppressor 
(Mantovani et al., 2006; Graham, 2009). It has emerged as a general strategy in recent 
years to tune the actions of cytokines and growth factors.  
 
The decoy chemokine receptors that had been reported are Duffy antigen for 
chemokines (DARC), D6 (which is also known as CCBP2) and also CCX-CKR (or 
CCRL1). Different from antibodies and small molecule receptor antagonists, chemokine 
decoy receptors generally have broad specificity of ligands that are recognized by 
different receptors (Mantovani et al., 2006a). In this study, DARC and D6 will be 
expressed and hence details of DARC and D6 are described as follows. 
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Adopted from Galzi et al. (2010) 
 
Figure 1.6 A global illustration of the routes taken by chemokines with different 
types of receptors 
Route 1: Chemokine binding with a typical specific receptor leads to signalling in 
the cell that expresses the receptor. 
Route 2: Chemokine binding with an interceptor intracellularly leads to either 
chemokine degradation or transcytosis. 
Route 3: Chemokine binding with a soluble interceptor leads to ligand 
sequestering. 
Route 4: Soluble interceptor binding prevents chemokine binding to 
glycoaminoglycans, which results in a collapse of the chemotactic 
gradient. 
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 1.4.1 D6 
D6 was first cloned from haematopoietic stem cells  (Nibbs et al., 1997) and 
placenta (Bonini et al., 1997) in the 1990s.  It is also known as CCBP2 (Locati et al., 
2005) or ACKR (atypical chemokine receptor) 2 (Wilson et al., 2017). It was highly 
expressed by endothelial cells of skin, gut and lung and also lymphatic endothelium, 
trophoblast, leukocyt, maglinant vascular tumuor, T-cell large granular lymphocyte 
leukemia cells, choriocarcinoma (Nibbs et al., 2001; Martinez de la Torre et al., 2007; 
Zeng et al., 2011) and human breast cancer cells (Wu et al., 2008).  
 
D6 was observed to bind almost all pro-inflammatory CC chemokines. However, 
it does not recognize and bind to homeostatic CC-chemokines or other families such as 
CXC-chemokines (Mantovani et al., 2006). The binding of D6 to its ligand happened in 
such a way that D6 takes part in ligand-independent constitutive internalization. D6 
enters cell through endosomal compartments rapidly upon binding with chemokine. 
Then, it detaches from the ligand and this made the internalized chemokines remain 
trapped in the cell. The trapped chemokines are then targeted for degradation by cellular 
organelle (Xu et al., 2007). At the same time, D6 recycles back to cell surface to bind 
new chemokine and rapidly enter the cell through endosomal compartments again 
(Chew et al., 2013). The repeated rounds of chemokine internalization leads to reduction 
of free extracellular pro-inflammatory chemokines and subsequently down regulate 
respective chemokine related biological activities (Figure 1.7). The binding mechanism 
of D6 to its ligands had been reported widely. Researches found that D6 took part in 
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chemokine degradation and at the same time reduced the inflammatory activity of CC 
chemokines (Savino et al., 2009). This agrees with the findings from Fra et al. (2003), 
Bonecchi et al. (2004) and Weber et al. (2004) that D6 can speedily internalize and 
degrade its ligands. Mantovani et al. (2006) also reported similar findings that D6 
mediates chemokine degradation but does not mediate chemokine transfer through cell 
monolayer. 
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Figure 1.7 The coordinated actions of DARC and D6 in peripheral tissues 
Adapated from Bonecchi et al. (2008) 
 Expression of DARC takes place on blood vessels and erythrocytes. Besides 
acting as chemokines’ depot on erythrocytes, it serves as decoy chemokine 
receptors on endothelial cells and transport chemokines through cell barriers by 
trancytosis. 
 
 D6 is expressed at lymphatic endothelium and leokocytes at lower levels. It acts 
as scavenger to degrade pro-inflammatory chemokines, preventig them from 
transfering to lymph nodes. 
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 D6 was a decoy chemokine receptor as it was found lacking of sequence motif 
used for G-protein coupling and also signaling functions of respective chemokine 
receptors (Mantovani et al., 2001).  D6 is structurally typical of chemokine receptor 
family and thus it has the similar gene structure with signaling CC chemokine receptors 
(Nibbs et al., 2003). However, alterations were observed in D6 conserved motif.  Instead 
of DRYLAIV motif on the second intracellular loop of GPCRs, it was observed being 
altered to DKYLEIV in D6 (Nibbs et al., 2003). DRYLAIV motif is essential for ligand-
induced signaling, having the conserved motif altered, making D6 a silent chemokine 
receptor.  Figure 1.8 showed the presence of D6 in chemokine system to compete with 
signaling chemokine receptors to bind with its ligand. The binding of D6 to its ligand 
will not elicit signal transduction so does the cascade of signaling pathways. Wu et al. 
(2008) reported that over expression of D6 reduced chemokines such as CCL2 and 
CCL5, subsequently inhibited proliferation of breast cancer cells in vitro and in vivo. 
The tumorigenesis of lung metastasis in vivo was observed to be inhibited too. 
Coexpression of D6 in invasive breast cancer cells was observed to be negatively 
correlated with lymph node status and tumor stage (Zeng et al., 2011). 
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Adopted from Mantovani et al. (2006) 
 
Figure 1.8 D6, the decoy chemokine receptor proteins compete with signaling 
chemokine receptor for ligands 
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 1.4.2 DARC 
DARC or Duffy Antigen was originally reported by Horuk et al. (1993) as the 
receptor on erythrocyte to bind chemokines in infection by malaria parasites, the 
Plasmodium vivax and P. knowlesi.  It was then well known and intensively studied in 
malaria research as its role is remarkable in this aspect. Pogo and Chaudhuri (2000) 
reported that human red blood cells which are Duffy-negative are resistant to malaria 
parasite infection. Similar results were reported by Miller et al. (1975) that the infection 
of malaria parasite in Duffy-positive individuals happened occasionally but Duffy-
negative individuals were not prone to the infection. All the four extracellular domains 
in DARC were shown to be involved in the interaction between DARC and chemokines 
but the first extracellular domain was found vital for the interactions of erythrocyte-
binding proteins from malarial parasites (Choe et al., 2005; Tournamille et al., 2003; 
Chitnis et al., 1996).  
 
DARC was found to be expressed by vascular endothelium, red blood cells and 
also several tumors (Wang et al., 2006; Galzi et al., 2010). The expression of DARC on 
endothelial cells suggested its role in vascular biology (Peiper et al., 1995). Rot (2005) 
showed that DARC interacts with many inflammatory chemokines on red blood cells 
and may act as a reservoir besides involving in transendothelial chemokine transport 
process (Figure 1.7). It was found to interact with 11 pro-inflammatory CXC and CC 
chemokines but not the homeostatic one (Gardner et al., 2004; Mantovani et al., 2001; 
Wang et al., 2006; Wu et al., 2008; Galzi et al., 2010). Being promiscuous chemokine 
